Skip to the page
Get started free

Data / Research funding / New York / Roswell Park Cancer Institute Corp

Roswell Park Cancer Institute Corp: 142 NIH awards ($215.6M) and 1 NSF award ($291.5K), fiscal years 2021 to 2026

Roswell Park Cancer Institute Corp in Buffalo, NY is funded under 142 NIH awards ($215.6M) and 1 NSF award ($291.5K) in the NIH and NSF award files, read 2026-11-04. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.

SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.

Get awards like theseWatch Roswell Park Cancer Institute Corp
UEI
YDWAYVVQHNK5
State
New York

Awards

143 awards in the window.

AwardAgencyInstitute or divisionFiscal yearAmount in windowStartEndPrincipal investigatorSource
Evaluating unmet survivorship needs: a multilevel assessment for a broad care networkNIHNational Cancer Institute2021 to 2025$23,369,596June 16, 1997April 30, 2026JOHNSON, CANDACE Sreporter.nih.gov
WNY Center for Research on Flavored Tobacco Products (CRoFT)NIHNational Cancer Institute2021 to 2022$7,947,183September 14, 2018August 31, 2024O'CONNOR, RICHARD Jreporter.nih.gov
Roswell Park Ovarian Cancer SPORENIHNational Cancer Institute2021 to 2025$7,930,009September 18, 2013August 31, 2027MOYSICH, KIRSTEN B.reporter.nih.gov
ONE Biorepository: Comprehensive Integrated Biobanking SystemsNIHOffice of the Director, National Institutes of Health2024$7,731,872September 18, 2024May 31, 2029AMBROSONE, CHRISTINE B.reporter.nih.gov
Targeting the Chemokine System to Sensitize Tumors to ImmunotherapyNIHNational Cancer Institute2021 to 2024$7,305,072March 3, 2020June 30, 2025KALINSKI, PAWELreporter.nih.gov
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology SettingNIHNational Cancer Institute2023 to 2025$7,201,689June 1, 2021May 31, 2027AMBROSONE, CHRISTINE B.reporter.nih.gov
Coordinating and Data Management Center for Acquired Resistance to Therapy NetworkNIHNational Cancer Institute2022 to 2025$6,584,333May 1, 2025April 30, 2026HUTSON, ALAN DAVIDreporter.nih.gov
Transcriptomic classification of non-muscle invasive bladder cancer and its clinical and prognostic implicationNIHNational Cancer Institute2022 to 2025$6,547,653September 1, 2025August 31, 2027TANG, LIreporter.nih.gov
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European AncestryNIHNational Cancer Institute2021 to 2024$4,181,635June 1, 2020May 31, 2025AMBROSONE, CHRISTINE B.reporter.nih.gov
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American WomenNIHNational Cancer Institute2021 to 2023$3,873,758February 1, 2019January 31, 2026YAO, SONGreporter.nih.gov
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor ImmunityNIHNational Cancer Institute2021 to 2025$3,445,316January 1, 2021December 31, 2026EVANS, SHARON Sreporter.nih.gov
Metformin for chemoprevention of lung cancer in obese subjects at high riskNIHNational Cancer Institute2021 to 2025$3,423,650August 1, 2021July 31, 2027YENDAMURI, SAIKRISHNAreporter.nih.gov
Advancing skin cancer prevention by tackling UV-induced clonogenic mutationsNIHNational Cancer Institute2021 to 2025$3,218,488February 3, 2021January 31, 2027WEI, LEIreporter.nih.gov
Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantationNIHNational Cancer Institute2021 to 2025$3,120,296August 1, 2021July 31, 2027HAHN, THERESA Ereporter.nih.gov
Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication AdherenceNIHNational Cancer Institute2022 to 2025$2,958,176December 15, 2021November 30, 2026BOUCHARD, ELIZABETHreporter.nih.gov
Radiogenomic Credentialing of Head and Neck Cancer ModelsNIHNational Cancer Institute2021 to 2025$2,932,365December 1, 2020November 30, 2026SESHADRI, MUKUNDreporter.nih.gov
Functional Significance of individual p53 mutations in determining the role of estrogen receptor beta in triple negative breast cancerNIHNational Cancer Institute2021 to 2025$2,894,996March 1, 2021February 28, 2027DAS, GOKUL M.reporter.nih.gov
Generation and analysis of new mouse models to determine novel therapeutic targets for Down syndrome-associated cognitive deficitsNIHEunice Kennedy Shriver National Institute of Child Health & Human Development2022 to 2025$2,832,381September 13, 2022August 31, 2027YU, EUGENEreporter.nih.gov
Assessing pharmacokinetic and pharmacodynamic variability of Δ9-tetrahydrocannabinol delivered from vaping products with and without concurrent use of nicotineNIHNational Institute on Drug Abuse2022 to 2025$2,720,537September 30, 2022June 30, 2027SMITH, DANIELLEreporter.nih.gov
RB tumor suppressor as a therapeutic target in ER-positive breast cancerNIHNational Cancer Institute2021 to 2024$2,698,348March 1, 2020February 28, 2026KNUDSEN, ERIKreporter.nih.gov
Implementation of evidence-based strategies to optimize HPV vaccination in rural primary care settingsNIHNational Institute on Minority Health and Health Disparities2022 to 2025$2,685,848August 21, 2022April 30, 2027RODRIGUEZ, ELISA MARIEreporter.nih.gov
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancerNIHNational Cancer Institute2022 to 2025$2,601,255August 24, 2022July 31, 2027ZSIROS, EMESEreporter.nih.gov
Understanding mechanisms and consequences of T cell co-receptor regulated RNA maturationNIHNational Institute of Allergy and Infectious Diseases2021 to 2025$2,586,142April 5, 2021March 31, 2026OLEJNICZAK, SCOTT HENRYreporter.nih.gov
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancerNIHNational Cancer Institute2022 to 2025$2,583,947April 1, 2021March 31, 2027BRENTJENS, RENIER JOSEPHreporter.nih.gov
STAG2 modulates environmental toxicant exposures and epigenomic heterogeneityNIHNational Institute of Environmental Health Sciences2022 to 2025$2,388,852March 20, 2022December 31, 2026OHM, JOYCE ELLENreporter.nih.gov
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint InhibitorsNIHNational Cancer Institute2023 to 2025$2,317,650September 14, 2023August 31, 2028HAHN, THERESA Ereporter.nih.gov
Hsp60 Regulation of Prostate Cancer ProgressionNIHNational Cancer Institute2021 to 2025$2,185,351September 1, 2021August 31, 2027CHANDRA, DHYANreporter.nih.gov
Role of type 2 immune response in pancreatic cancer tumorigenesisNIHNational Cancer Institute2021 to 2025$2,165,563July 15, 2021June 30, 2026DEY, PRASENJITreporter.nih.gov
Delineating the dystopian nature of the cell cycle in cancerNIHNational Cancer Institute2022 to 2025$2,136,375June 3, 2022May 31, 2027KNUDSEN, ERIKreporter.nih.gov
Advancing Cancer Therapy through Groundbreaking Research in Radiation BiologyNIHNational Cancer Institute2023 to 2025$2,114,155January 16, 2016August 31, 2029KIRSCH, DAVID GUYreporter.nih.gov
TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumorsNIHNational Cancer Institute2023 to 2025$2,103,321June 9, 2023May 31, 2028BRACKETT, CRAIG M.reporter.nih.gov
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology SettingNIHNational Cancer Institute2021 to 2022$2,064,137June 1, 2021May 31, 2023YAO, SONGreporter.nih.gov
Inhibition of Radiation-Induced Coronary Microvascular DiseaseNIHNational Heart, Lung, and Blood Institute2021 to 2025$2,050,609January 15, 2021December 31, 2026POKHAREL, SARASWATIreporter.nih.gov
Acquisition of a 7T MR scanner for Translational Imaging Research at Roswell ParkNIHOffice of the Director, National Institutes of Health2021$2,000,000April 1, 2021March 31, 2023SESHADRI, MUKUNDreporter.nih.gov
Network Lead Academic Participating Site Grant from the Roswell Park Cancer InstituteNIHNational Cancer Institute2021 to 2025$1,984,547March 6, 2019February 28, 2026LEVINE, ELLIS Greporter.nih.gov
Leveraging the GTP Biosynthetic Pathway for Anti-Tumor TherapiesNIHNational Cancer Institute2021 to 2025$1,906,679December 10, 2020April 30, 2026BIANCHI-SMIRAGLIA, ANNAreporter.nih.gov
Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancerNIHNational Cancer Institute2021 to 2025$1,900,860April 1, 2021March 31, 2027DASGUPTA, SUBHAMOYreporter.nih.gov
Relationships between parity, breastfeeding and ER- breast cancer in African American women: Elucidating the biologic underpinnings at the molecular and cellular level.NIHNational Cancer Institute2021 to 2023$1,829,705December 4, 2018November 30, 2024AMBROSONE, CHRISTINE B.reporter.nih.gov
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancerNIHNational Cancer Institute2021 to 2024$1,810,625May 22, 2019April 30, 2026GOODRICH, DAVID W.reporter.nih.gov
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa CellsNIHNational Cancer Institute2021 to 2025$1,753,253June 1, 2019March 31, 2030TANG, DEAN G.reporter.nih.gov
Targeting adrenergic stress pathways to Increase tumor sensitivity to radiation and promote development of an anti-tumor immune responseNIHNational Cancer Institute2021 to 2023$1,659,234February 8, 2019January 31, 2025REPASKY, ELIZABETH Areporter.nih.gov
Novel synthetic lethality strategy for TP53 mutant colorectal cancerNIHNational Cancer Institute2023 to 2025$1,631,453August 10, 2023July 31, 2027FOUNTZILAS, CHRISTOSreporter.nih.gov
Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCINIHNational Cancer Institute2021 to 2024$1,608,949January 1, 2024August 31, 2025HUTSON, ALAN DAVIDreporter.nih.gov
Dissecting the Mechanism of SETDB1 and its K867 Monoubiquitination in Lung Cancer ProgressionNIHNational Cancer Institute2022 to 2025$1,579,675August 5, 2022July 31, 2027FANG, JIAreporter.nih.gov
Synchronized brain dynamics and eye movement trajectory for objective evaluation of robot-assisted surgical skillsNIHNational Institute of Biomedical Imaging and Bioengineering2021 to 2023$1,531,360April 1, 2020January 31, 2026BESHARAT SHAFIEI, SOMAYEHreporter.nih.gov
Long noncoding RNA regulations in breast cancer among African-American womenNIHNational Cancer Institute2021 to 2024$1,506,566July 1, 2020June 30, 2025GONG, ZHIHONGreporter.nih.gov
Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironmentNIHNational Cancer Institute2023 to 2025$1,490,387July 7, 2023June 30, 2028WITKIEWICZ, AGNIESZKAreporter.nih.gov
Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients with Inoperable Malignant Central Airway ObstructionNIHNational Cancer Institute2024 to 2025$1,450,785March 1, 2024February 28, 2029SHAFIRSTEIN, GALreporter.nih.gov
Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinomaNIHNational Cancer Institute2023 to 2025$1,441,755February 3, 2023December 31, 2027ABEL, ETHAN VINCENTreporter.nih.gov
MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric MedicationNIHNational Cancer Institute2024 to 2025$1,434,826April 1, 2024March 31, 2029BOUCHARD, ELIZABETHreporter.nih.gov
Therapeutic implication of RB1 loss in bladder cancerNIHNational Cancer Institute2021 to 2025$1,428,645March 5, 2021February 28, 2027LI, QIANGreporter.nih.gov
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantationNIHNational Heart, Lung, and Blood Institute2024 to 2025$1,420,921April 1, 2023March 31, 2028BETTS, BRIAN Creporter.nih.gov
Epigenetic aging as a driver of racial disparities in early onset prostate cancerNIHNational Cancer Institute2024 to 2025$1,416,138September 20, 2024August 31, 2029WOLOSZYNSKA-READ, ANNAreporter.nih.gov
Associate-Director Flow and Image Cytometry Roswell Park ComprehensiveCancer CenterNIHNational Cancer Institute2022 to 2025$1,368,428September 20, 2016August 31, 2027MINDERMAN, HANSreporter.nih.gov
Investigating how stress induced changes in maternal serotonin affect offspring development and stress resilienceNIHNational Institute of Mental Health2023 to 2025$1,287,750April 1, 2022February 28, 2027PRAHLAD, VEENAreporter.nih.gov
Tumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPCNIHNational Cancer Institute2021 to 2023$1,283,103March 1, 2019August 31, 2024TANG, DEAN G.reporter.nih.gov
The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast CancerNIHNational Cancer Institute2023 to 2025$1,250,312April 26, 2023March 31, 2028ATANASSOV, BOYKO Sreporter.nih.gov
Preoperative Respiratory Muscle Training to Prevent Postoperative Pulmonary Complications in Patients Undergoing Resection for Lung CancerNIHNational Cancer Institute2021 to 2022$1,233,487September 17, 2018August 31, 2024RAY, ANDREW DONALDreporter.nih.gov
Targeting retrotransposons for improved treatment of refractory childhood cancerNIHNational Cancer Institute2024 to 2025$1,186,599June 5, 2024May 31, 2029GUDKOV, ANDREI Vreporter.nih.gov
ST6Gal-1 Sialyltransferase in InflammationNIHNational Institute of Allergy and Infectious Diseases2021$1,169,867June 25, 2020August 31, 2023LAU, JOSEPH TYreporter.nih.gov
Sensitizing high grade serous cancers to immunotherapy through the induction of DNA damageNIHNational Cancer Institute2022 to 2024$1,141,919July 1, 2020June 30, 2026MCLEAN, KARENreporter.nih.gov
Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitorsNIHNational Cancer Institute2021 to 2022$1,122,971December 19, 2017November 30, 2023REPASKY, ELIZABETH Areporter.nih.gov
Summer Research Experiences in Quantitative Cancer Sciences and Emerging TechnologiesNIHNational Cancer Institute2021 to 2025$1,049,113September 1, 2014July 31, 2030HERSHBERGER, PAMELA Areporter.nih.gov
Enhancing Relapse Prevention with rTMS: Dose-Response Parameters for Smoking CessationNIHNational Cancer Institute2021 to 2022$1,047,080June 1, 2018May 31, 2025SHEFFER, CHRISTINE ELIZABETHreporter.nih.gov
The Immunomodulatory Function of Cyclin E1 in Ovarian Cancer and Therapeutic TargetingNIHNational Cancer Institute2024 to 2025$1,011,702April 1, 2024March 31, 2029DING, LIYAreporter.nih.gov
Development of New Technologies at Roswell Park to Further Cancer-Based Research and Treatment Through Genome ModificationNIHNational Cancer Institute2023 to 2025$974,604September 19, 2023August 31, 2028STABLEWSKI, AIMEE Breporter.nih.gov
The Genetic Basis of Human DNA Replication TimingNIHNational Institute of General Medical Sciences2024 to 2025$916,080May 1, 2023February 29, 2028KOREN, AMNONreporter.nih.gov
Cancer Immunoprevention Network (CIP-Net) Resource Coordinating CenterNIHNational Cancer Institute2025$825,857September 1, 2025August 31, 2030HUTSON, ALAN DAVIDreporter.nih.gov
Assessing the impact of the substantial equivalence mechanism on the cigarette and cigar marketsNIHNational Cancer Institute2025$816,307September 15, 2025August 31, 2030O'CONNOR, RICHARD Jreporter.nih.gov
Induction of interferon response by chromatin damaging anti-cancer therapyNIHNational Cancer Institute2024 to 2025$793,762December 1, 2023November 30, 2028GUROVA, KATERINA Vreporter.nih.gov
Improving targeted therapy in FLT3-mutated AMLNIHNational Cancer Institute2021 to 2024$774,414July 1, 2020December 31, 2025SUNG, PAMELA JEANNETTEreporter.nih.gov
Genetic susceptibility to Barrett's esophagus: From GWAS to biologyNIHNational Institute of Diabetes and Digestive and Kidney Diseases2022$762,225December 21, 2021June 30, 2022BUAS, MATTHEW FRANKreporter.nih.gov
Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) ResponsesNIHNational Heart, Lung, and Blood Institute2022 to 2024$747,000June 1, 2022May 31, 2026MOHAMMADPOUR, HEMNreporter.nih.gov
Replication Licensing in Genome Stability, Cancer and AgingNIHNational Cancer Institute2021 to 2022$727,101April 6, 2008June 30, 2024KNUDSEN, ERIKreporter.nih.gov
Determining the Impact of Metabolic Adaptations on the Immune-Tumor Microenvironment in Metastatic Breast CancerNIHNational Cancer Institute2025$719,799January 1, 2025December 31, 2029DASGUPTA, SUBHAMOYreporter.nih.gov
Multidisciplinary Approaches to Tumor ImmunologyNIHNational Cancer Institute2021 to 2025$718,796July 1, 2001August 31, 2028ABRAMS, SCOTT I.reporter.nih.gov
A scalable cruciferous vegetable intervention to reduce bladder cancer recurrence and progressionNIHNational Cancer Institute2025$717,150January 1, 2025December 31, 2029YEARY, KAREN HYE-CHEON KIMreporter.nih.gov
Decipher the Molecular Mechanisms of Breast Cancer Bone MetastasisNIHNational Cancer Institute2025$700,690April 1, 2025March 31, 2030WANG, HAIreporter.nih.gov
Overcoming Drug Resistance in HER2-positive Breast CancerNIHNational Cancer Institute2021$551,376July 1, 2020April 10, 2022ZHANG, YUESHENGreporter.nih.gov
Preparing Nurse Scientists to Lead the Future of Oncology ResearchNIHNational Cancer Institute2024 to 2025$545,604September 1, 2024August 31, 2029REPASKY, ELIZABETH Areporter.nih.gov
Impact of novel Heat-not-Burn cigarettes on pulmonary inflammation and immunityNIHNational Heart, Lung, and Blood Institute2021$497,698May 20, 2019April 30, 2024THANAVALA, YASMINreporter.nih.gov
Director Genomics Shared ResourceNIHNational Cancer Institute2024 to 2025$472,006September 1, 2024August 31, 2029SINGH, PRASHANT KUMARreporter.nih.gov
Radiation-induced Salivary Gland Vascular Injury: Mechanisms and InterventionsNIHNational Institute of Dental & Craniofacial Research2022$471,502September 22, 2022September 21, 2024SESHADRI, MUKUNDreporter.nih.gov
Identifying Chemo-Neoepitopes for Immunotherapy Interventions Against Triple-Negative Breast CancerNIHNational Cancer Institute2024$460,977June 1, 2024May 31, 2026IONOV, YURIJreporter.nih.gov
Combined inhibition of ATR and p110β as Therapy in PTEN-deficient Prostate CancerNIHNational Cancer Institute2024 to 2025$446,112March 1, 2024August 31, 2026DING, LIYAreporter.nih.gov
Assessment of consumer response to smokeless tobacco modified risk marketing ordersNIHNational Cancer Institute2024$443,509August 1, 2024July 31, 2026O'CONNOR, RICHARD Jreporter.nih.gov
Tumor and immune cell co-evolutionary dynamics as a source of racial disparities in breast cancerNIHNational Cancer Institute2022 to 2023$442,057August 1, 2022July 31, 2025OMILIAN, ANGELAreporter.nih.gov
Development of a Novel Immunotherapy Platform for Triple-Negative Breast CancerNIHNational Cancer Institute2021 to 2022$428,554August 6, 2021June 30, 2024BRACKETT, CRAIG M.reporter.nih.gov
Development of TLR5 agonist based approaches to boost chemo-immunotherapy by modulating immunosuppressive networksNIHNational Cancer Institute2022 to 2023$428,554December 23, 2021November 30, 2024BRACKETT, CRAIG M.reporter.nih.gov
A Novel Treatment Strategy for Metastatic Breast CancerNIHNational Cancer Institute2022 to 2023$428,554December 15, 2021November 30, 2024BAKIN, ANDREI V.reporter.nih.gov
Optical Surface Applicator Light Dosimetry for Ruthenium-based Photosensitizer Mediated Intraoperative Photodynamic TherapyNIHNational Cancer Institute2021 to 2022$421,960July 20, 2021June 30, 2024SHAFIRSTEIN, GALreporter.nih.gov
Synthetic rocaglates as promising therapeutic agents for aggressive hematological malignanciesNIHNational Cancer Institute2021 to 2022$415,248February 8, 2021January 31, 2024FU, KAIreporter.nih.gov
Assessing the impacts of the four 2019/2020 US federal-level tobacco control actions: flavors, youth marketing, youth access, and Tobacco 21NIHNational Institute on Drug Abuse2021 to 2022$414,210May 1, 2021April 30, 2024KASZA, KARIN Areporter.nih.gov
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumorsNIHNational Cancer Institute2021$410,221August 1, 2021December 24, 2021ITO, FUMITOreporter.nih.gov
Flaxseed effects on gut microbial metabolism and circulating inflammation-related metabolic profiles in African American and non-Hispanic white womenNIHNational Center for Complementary & Integrative Health2021$398,590September 17, 2018February 28, 2023TANG, LIreporter.nih.gov
The role of TAZ in breast cancer initiation and progressionNIHNational Cancer Institute2021$397,005July 1, 2017June 30, 2023ZHANG, JIANMINreporter.nih.gov
Common Genetically Altered Pathways as Targets for Therapy in Pancreatic CancerNIHNational Cancer Institute2021$392,993February 1, 2017January 31, 2023WITKIEWICZ, AGNIESZKAreporter.nih.gov
Targeting Mdm2-MdmX E3 Ligase for Treatment of Drug-Resistant LymphomaNIHNational Cancer Institute2021$392,992April 1, 2017March 31, 2023WANG, XINJIANGreporter.nih.gov
Evaluating candidate mediators of prostate cancer metastasis and neuro endocrine prostate cancer (NEPC) trans differentiationNIHNational Cancer Institute2021 to 2023$390,636September 14, 2018August 31, 2024CHINNAM, MEENALAKSHMIreporter.nih.gov
Regulation of non-proteolytic ubiquitination in cancer chemoresistance and progressionNIHNational Cancer Institute2021$384,758July 1, 2017June 30, 2024KNUDSEN, ERIKreporter.nih.gov
The Influence of Social Network Size, Composition and Function on Psychological Outcomes of Pediatric Cancer Caregiving: Relationships across Time and around Periods of DistressNIHNational Cancer Institute2021$378,766June 1, 2017May 31, 2023BOUCHARD, ELIZABETHreporter.nih.gov
Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALLNIHNational Cancer Institute2024 to 2025$368,300July 17, 2024June 30, 2029NISWANDER, LISA MADALENreporter.nih.gov
Acquisition of a calScreener Isothermal Microcalorimetry System for Translational Cancer Metabolism Research at Roswell ParkNIHOffice of the Director, National Institutes of Health2023$310,000July 15, 2023July 14, 2025REPASKY, ELIZABETH Areporter.nih.gov
Digital Spatial ProfilerNIHOffice of the Director, National Institutes of Health2021$295,000September 1, 2021August 31, 2023WITKIEWICZ, AGNIESZKAreporter.nih.gov
The Evolution of DNA Replication Timing in Great ApesNSFDivision of Molecular and Cellular Biosciences2024$291,512January 1, 2024June 30, 2026Amnon Korennsf.gov
Do E-cigarette Design Features Impact Cigarette Initiation, Cessation & Relapse?NIHNational Institute on Drug Abuse2021$252,300August 1, 2020July 31, 2023KASZA, KARIN Areporter.nih.gov
Targeting Malic Enzyme 3 as a Synthetic Lethality Target in Pancreatic CancerNIHNational Cancer Institute2021$249,000September 1, 2019August 31, 2022DEY, PRASENJITreporter.nih.gov
Correlative efficacy, biomarker, and mechanistic studies associated with a phase Ib/II clinical trial of treating mCRPC patients with enzalutamide and VenetoclaxNIHNational Cancer Institute2021$245,017December 1, 2019February 28, 2022TANG, DEAN G.reporter.nih.gov
Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GvT) ResponsesNIHNational Heart, Lung, and Blood Institute2021 to 2022$235,728March 5, 2021May 31, 2022MOHAMMADPOUR, HEMNreporter.nih.gov
Personal factors, product characteristics, and changes in biomarkers of exposure among cigarette smokers who switch to noncombustible tobacco products.NIHNational Cancer Institute2021$210,250September 20, 2021July 6, 2022FELICIONE, NICHOLAS JOHNreporter.nih.gov
Early Detection and Immunomodulation of PD-1 Inhibitor Induced CardiotoxicityNIHNational Heart, Lung, and Blood Institute2021$209,275August 10, 2020July 31, 2023POKHAREL, SARASWATIreporter.nih.gov
A novel sugar-sweetened beverage reduction intervention for Native American menNIHNational Institute of Nursing Research2021$195,316September 15, 2020January 31, 2024HARING, RODNEY Creporter.nih.gov
CRISPR-mediated engineering and pilot study of mouse mutants of the bitter taste receptor genesNIHNational Center for Advancing Translational Sciences2022$182,279June 17, 2022May 16, 2025YU, EUGENEreporter.nih.gov
The role of ceramide kinase in metastasis growth from aggressive breast cancerNIHNational Cancer Institute2023 to 2024$173,500May 1, 2023April 30, 2026HAIT, NITAIreporter.nih.gov
Identifying the role of interferon and interferon-regulated chemokines in stress-induced immunosuppression in triple negative breast cancerNIHNational Center for Advancing Translational Sciences2023$173,500September 1, 2023August 31, 2025GANDHI, SHIPRAreporter.nih.gov
Linking lifestyles with tumor immune profiles to identify strategies for improving breast cancer outcomesNIHNational Cancer Institute2024 to 2025$173,500March 1, 2024February 28, 2026CANNIOTO, RIKKIreporter.nih.gov
Investigation of the effects of CXCR1/2 inhibition on the immune microenvironment of patients with multiple myelomaNIHNational Cancer Institute2025$173,500August 7, 2025July 31, 2027HILLENGASS, JENSreporter.nih.gov
CD28-mediated Regulation of Multiple Myeloma Cell Proliferation and SurvivalNIHNational Cancer Institute2021$172,309September 12, 2007July 14, 2021LEE, KELVIN P.reporter.nih.gov
The impact of chronic stress on radiation induced cell death and the anti-tumor immune responseNIHNational Cancer Institute2021 to 2024$169,092September 1, 2021August 31, 2025MACDONALD, CAMERON RIKERreporter.nih.gov
Investing in Research Software Engineering for Expert Development and Dissemination of BioconductorNIHNational Library of Medicine2025$168,448September 3, 2025August 31, 2028KERN, LORIreporter.nih.gov
Examining the impact of endogenous CD28 signaling on CAR T cellsNIHNational Cancer Institute2021 to 2022$168,200December 11, 2020November 30, 2022OLEJNICZAK, SCOTT HENRYreporter.nih.gov
Novel 7SK non-coding RNA fusions in soft tissue sarcomas to tumorigenesisNIHNational Cancer Institute2021 to 2022$168,200March 1, 2021February 28, 2023OHM, JOYCE ELLENreporter.nih.gov
Stress-induced immunosuppression via downregulation of interferon in triple negative breast cancerNIHNational Cancer Institute2024$157,771July 1, 2024February 28, 2025GANDHI, SHIPRAreporter.nih.gov
The Wnt-IRF8 axis: a Novel Regulator of Myeloid-Derived Suppressor Cell BiologyNIHNational Cancer Institute2021 to 2023$130,763September 1, 2020June 30, 2024KRAMER, ELLIOT DAVIDreporter.nih.gov
Understanding the role of β2AR-signaling on ILC2 differentiation/plasticity and its implications in cancer progressionNIHNational Cancer Institute2023 to 2025$120,842September 1, 2023August 31, 2027CHOI, JEE EUNreporter.nih.gov
The Role of Tumor-Infiltrating Immune Cells and Estrogen Receptor Expression in Racial Disparities in Breast Cancer Biology.NIHNational Cancer Institute2021$87,350December 1, 2019November 30, 2022OMILIAN, ANGELAreporter.nih.gov
Precision vitamin D supplementation as a novel approach to prevent lung cancer progressionNIHNational Cancer Institute2021$87,350March 17, 2020February 28, 2023HERSHBERGER, PAMELA Areporter.nih.gov
Role of serotonergic-activation of heat shock transcription factor in the regulation of age-related protein misfolding and toxicity in mammalian systemsNIHNational Institute on Aging2022$84,734September 5, 2021November 30, 2025PRAHLAD, VEENAreporter.nih.gov
Examining the impact of laboratory housing temperature on murine CD28 and the response to anti-PD-1NIHNational Cancer Institute2023 to 2025$77,689September 1, 2023November 30, 2025JAMES, CAITLIN Mreporter.nih.gov
Metabolic Reprogramming of Myeloid Cells to Enhance Cancer ImmunotherapyNIHNational Cancer Institute2024 to 2025$69,648September 1, 2024August 31, 2026MORREALE, BRIAN GEORGEreporter.nih.gov
Developing Imaging Biomarkers of Oral Squamous Cell Carcinoma Response to ImmunotherapyNIHNational Institute of Dental & Craniofacial Research2021 to 2022$64,083June 1, 2021May 31, 2023DEJOHN, CELIAreporter.nih.gov
Impact of benzodiazepines on the pancreatic tumor microenvironmentNIHNational Cancer Institute2022 to 2023$52,752January 1, 2022August 18, 2023CORNWELL, ABIGAIL CARISSAreporter.nih.gov
Combating Cetuximab Resistance in Colorectal CancerNIHNational Cancer Institute2021$43,397April 1, 2017March 31, 2022ZHANG, YUESHENGreporter.nih.gov
Genetic and Ancestral Determinants of Pathological and Molecular Tumor Immune Phenotypes in A Multi-Ethnic Population of Breast Cancer Patients: An Evolutionary PerspectiveNIHNational Cancer Institute2025$42,256September 1, 2025August 31, 2027FIORICA, PETER Nreporter.nih.gov
Impact of Numeracy on Risk Perceptions of Tobacco-Related DiseasesNIHNational Cancer Institute2022 to 2023$37,573August 1, 2022September 19, 2023DIAZ, DESTINYreporter.nih.gov
TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast CancerNIHNational Cancer Institute2024$37,548January 1, 2024May 29, 2024ZHANG, JIANMINreporter.nih.gov
Modulating costimulation in CAR T cells to enhance antitumor efficacyNIHNational Cancer Institute2025$35,090September 1, 2025August 31, 2027TONG, JASON Hreporter.nih.gov
Mechanisms of Acquired Resistance to PD-L1-Targeted Therapy in CancerNIHNational Cancer Institute2021$31,538April 1, 2020March 31, 2022SHI, YUHAOreporter.nih.gov
Leveraging polyamine metabolic stress to enhance sensitivity to epigenetic therapy for Prostate CancerNIHNational Cancer Institute2021$31,538August 1, 2020July 31, 2022ROWSAM, ARYNreporter.nih.gov
Transcriptional Control of Macrophage-Mediated Mechanisms of MetastasisNIHNational Cancer Institute2021$30,820September 1, 2019August 31, 2022TZETZO, STEPHANIEreporter.nih.gov
Leveraging tissue-specific regulatory maps and network-assisted analysis to identify novel genetic risk loci for esophageal adenocarcinomaNIHNational Cancer Institute2022$26,350March 3, 2022June 30, 2022BUAS, MATTHEW FRANKreporter.nih.gov
Decoding the nuclear metabolic processes regulating gene transcriptionNIHNational Cancer Institute2024$20,175June 1, 2023May 31, 2024DASGUPTA, SUBHAMOYreporter.nih.gov
Overcoming stress driven suppression of the anti-tumor immune response in cancer - understanding the MDSC piece of the puzzleNIHNational Cancer Institute2021$12,238January 1, 2020February 10, 2021MOHAMMADPOUR, HEMNreporter.nih.gov

Funding by fiscal year

Fiscal yearNIH awardsNIH amountNSF awardsNSF amount
202566$42,221,5140$0
202472$49,014,9670$0
202368$42,612,1100$0
202271$39,303,7531$291,512
202174$42,468,7940$0

Open federal funding opportunities

From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.

Open opportunityNumberAgencyListingClosesAward ceilingWhy it matches
Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)PA-24-254NIHJuly 12, 2027Not listedNotice number printed on 1 award here
NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)RFA-OD-24-011NIHDecember 4, 2026Not listedNotice number printed on 1 award here
Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)PAR-26-152NIH93.395November 11, 2026Not listedSame assistance listing 93.395 as 30 awards here
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed)PAR-27-088NIH93.395November 20, 2026Not listedSame assistance listing 93.395 as 30 awards here
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)PAR-24-214NIH93.395January 7, 2027$375,000Same assistance listing 93.395 as 30 awards here
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)PAR-25-079NIH93.395January 7, 2027$500,000Same assistance listing 93.395 as 30 awards here
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)PAR-25-081NIH93.395January 7, 2027$499,999Same assistance listing 93.395 as 30 awards here
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)RFA-CA-27-005NIH93.395January 11, 2027$700,000Same assistance listing 93.395 as 30 awards here
Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)PAR-27-009NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 30 awards here
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)RFA-CA-26-010NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 30 awards here
Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)RFA-CA-27-003NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 30 awards here
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)PA-27-100NIH93.395April 5, 2027Not listedSame assistance listing 93.395 as 30 awards here
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)PA-27-102NIH93.395April 5, 2027Not listedSame assistance listing 93.395 as 30 awards here
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)RFA-CA-28-003NIH93.395June 11, 2027$600,000Same assistance listing 93.395 as 30 awards here
Successor-in-Interest (Type 6 Parent Clinical Trial Optional)PA-24-253NIH93.395July 17, 2027Not listedSame assistance listing 93.395 as 30 awards here
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)PA-25-080NIH93.395September 7, 2027Not listedSame assistance listing 93.395 as 30 awards here
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)PAR-24-325NIH93.395September 7, 2027Not listedSame assistance listing 93.395 as 30 awards here
Investigator-Focused Award (Parent R35)PAR-28-037NIH93.395October 4, 2027Not listedSame assistance listing 93.395 as 30 awards here
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)RFA-CA-27-019NIH93.395October 19, 2027$300,000Same assistance listing 93.395 as 30 awards here
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)PAR-27-078NIH93.395October 25, 2027$375,000Same assistance listing 93.395 as 30 awards here

Topics of its NIH awards

Updated November 4, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-04). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.